A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors

The anti-ErbB2 antibodies trastuzumab and pertuzumab in combination have recently been approved for the treatment of patients with ErbB2-positive metastatic breast cancer. Pertuzumab, which binds to ErbB2 near the center of domain II, and trastuzumab, which binds to the juxtamembrane region of ErbB2...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Y, Zheng, L, Yang, Y, Wang, H, Dong, J, Wang, C, Zhang, Y, Yu, X, Wang, L, Xia, T, Zhang, D, Guo, Y, Li, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815051/
https://www.ncbi.nlm.nih.gov/pubmed/26999718
http://dx.doi.org/10.1038/oncsis.2016.25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815051/
https://www.ncbi.nlm.nih.gov/pubmed/26999718
http://dx.doi.org/10.1038/oncsis.2016.25

Ejemplares similares